Cabaletta Bio, Inc.
CABAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Valued at $554.4M, CABA is a small-cap name in its sector. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclerosis, mucocutaneous and mucosal pemphigus vulgaris (PV), systemic sclerosis, and generalized myasthenia gravis.
Market Cap
$554.4M
Beta
3.26
P/E (TTM)
—
P/E (Fwd)
-2.21
EPS (TTM)
$-1.38
EPS (Fwd)
$-1.48
ROE
-93.2%
ROA
-48.2%
Cash
$225.1M
Total Debt
$25.7M
Free CF
-$98.3M
52W Change
99.4%
Annual Financials
Cash vs Debt
Where CABA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CABA finished 15.91% above its 150-day moving average ($3.08) and 23.10% above its 200-day moving average ($2.90). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CABA overbought or oversold?
At the September 3, 2026 close, CABA's RSI(14) was 77.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $225.1M in cash comfortably exceeding the $25.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$98.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -93.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 3.26 means CABA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cabaletta Bio, Inc. and its sector.